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Abstract
Background: Pituitary corticotroph tumors secrete excess adrenocorticotrophic hormone (ACTH) resulting in Cushing’s
disease (CD). Standard treatment includes surgery and, if not successful, radiotherapy, both of which have undesirable side
effects and frequent recurrence of the tumor. Pharmacotherapy using PPARc agonists, dopamine receptor agonists, retinoic
acid or somatostatin analogs is still experimental. Curcumin, a commonly used food additive in South Asian cooking, has
potent growth inhibitory effects on cell proliferation. Our laboratory recently demonstrated that curcumin inhibited growth
and induced apoptosis in prolactin- and growth hormone-producing tumor cells [1]. Subsequently, Schaaf et.al. confirmed
our findings and also showed the in vivo effectiveness of curcumin to suppress pituitary tumorigenesis. However the
molecular mechanism that mediate this effect of curcumin are still unknown.
Principal Findings: Using the mouse corticotroph tumor cells, AtT20 cells, we report that curcumin had a robust, irreversible
inhibitory effect on cell proliferation and clonogenic property. The curcumin-induced growth inhibition was accompanied
by decreased NFkB activity. Further, curcumin down-regulated the pro-survival protein Bcl-xL, depolarized the
mitochondrial membrane, increased PARP cleavage, which led to apoptotic cell death. Finally, curcumin had a
concentration-dependent suppressive effect on ACTH secretion from AtT20 cells.
Conclusion: The ability of curcumin to inhibit NFkB and induce apoptosis in pituitary corticotroph tumor cells leads us to
propose developing it as a novel therapeutic agent for the treatment of CD.
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Introduction
Pituitary tumors, although not generally metastatic in nature, do
result in morbidity due to both altered hormonal patterns as well as
side effects of therapy [2]. Pituitary corticotroph tumors secrete excess
ACTH resulting in CD. The progression of CD is accompanied by
several pathological conditions including diabetes, osteoporosis and
hypertension [3]. To date no standard reliable medical therapy exists
to decrease ACTH secretion in CD. The commonly accepted
approach for treatment is still pituitary surgery followed by radiation,
and disease relapse is a common outcome with both. Medical
therapiesarestillexperimentalwithapproachestosuppressingACTH
secretion including, D2R agonists, somatostatin receptor antagonist,
thiazolidinediones (PPARc agonists) and retinoic acid [4–7].
Increased expression of the pro-survival protein, Bcl-2 is a
common occurrence in pituitary tumors [8]. The pro-survival Bcl-
2 family of proteins (Bcl-2, Bcl-xL and Mcl-1), are target genes of
NFkB, and confer resistance to mitochondrial apoptosis. For
example neuronal cells overexpressing Bcl-2 fail to undergo
dopamine-induced apoptosis [9].
Curcumin, in addition to being a food additive, has been used as
a medicinalagent intheancient Indian system of Ayurvedicmedicine.
It isa biphenolic compound,derived from theplantCurcuma longa,o f
the Zingiberaceae (ginger) family, and imparts the distinct yellow color
to Indian curries. In the Indian population, it is estimated that the
averagedailyconsumptionofcurcuminis60–100 mg[10].Itisnow
well accepted that one of the mechanisms by which curcumin
suppresses tumor growth is by inhibiting constitutively activated
NFkB [11]. Currently, the anti-tumor properties of curcumin are
being evaluated in several clinical trials, including pancreatic and
colon cancer and also for Alzheimer disease [12]. The selectivity of
curcumin to target tumor cells, as demonstrated by its ability to
induce apoptosis in hepatocellular carcinoma while having no effect
on normal hepatocytes, makes it an attractive pharmacotherapeutic
agent [13,14]. Further, in Phase I clinical trials in humans,
curcumin was tolerated up to 8000 mg/day [15].
We recently demonstrated that curcumin was effective at
suppressing the proliferation of prolactin- and growth hormone-
producing pituitary tumor cells [1]. A recent report confirmed our
original in vitro observations and further demonstrated the in vivo
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both a xenograft tumor model as well as in primary cell cultures of
human pituitary tumors [16]. However, the molecular mechanism
by which curcumin induces apoptosis in pituitary tumor cells
remains unknown.
In the present study we examined the growth suppressive effect of
curcumin on a mouse corticotroph tumor cell line, AtT20 cells. We
report that curcumin inhibits constitutively active NFkB, decreases
expression of pro-survival protein Bcl-xL, resulting in mitochondrial
apoptosis. In addition curcumin potently suppressed ACTH
secretion. The ability of curcumin to suppress proliferation as well
as attenuate hormone secretion, leads us to propose developing
curcumin as a novel therapeutic agent in the management of CD.
Results
Curcumin suppresses cell proliferation and clonogenic
ability of AtT20 cells
We first examined the effect of curcumin on AtT20 cell
proliferation. AtT20 cells were treated with curcumin (2.5–
200 mM) and cell proliferation was assessed after 4 days. Our
results show (Fig. 1A) that in a concentration-dependent manner
Figure 1. Curcumin suppresses cell proliferation and clonogenic ability of AtT20 cells. (A) AtT20 cells were treated with the indicated
concentrations of curcumin and cell proliferation was determined by MTT assay after 4 days. Data were calculated as % of vehicle control and
expressed as mean 6SEM of 3 independent experiments each performed with at least 4 replicates. * indicates significant differences from control,
(p,0.05). (B) AtT20 cells were treated with either vehicle or curcumin (5, 10 and 50 mM) for 24 hrs. Cells were trypsinized, washed and re-plated in
DMEM medium containing 10% FBS. Cell proliferation was assessed after 4 days. Data were calculated as % of vehicle control and expressed as mean
6SEM of 3 independent experiments each performed with at least 4 replicates. * indicates significant differences from control (p,0.05). (C) AtT20
cells were seeded (1000–3000 cells/well) in a six well plate in complete growth medium containing 10% FBS. Cells were allowed to adhere for 24 hrs,
after which medium was replaced with fresh growth medium, containing 10% FBS, together with the indicated concentrations of curcumin. Medium
was changed every 3 to 4 days, and colony formation was monitored over a 14–21 day period. Colony formation was detected by crystal violet
staining and subsequently photographed. Data shown is from a single experiment, and is a representative of 3 independent experiments yielding
similar results. (D) To quantitate colony formation, the number of colonies (each colony consisting of 50 cells or more) in 4 random fields were
counted. The average was obtained, and decreases from 0 mM curcumin were calculated and are expressed as % of control. Each value is the mean
6SEM of 3 separate experiments. * indicates significant difference from control, (p,0.05).
doi:10.1371/journal.pone.0009893.g001
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tion (28.68%; p,0.005) of cell proliferation was observed with
20 mM, and maximal inhibition (89.63%; p,0.005) being
observed with 100 mM curcumin. We next questioned whether
the growth inhibitory effect of curcumin on corticotroph tumor
cell proliferation persisted upon removal of curcumin. AtT20 cells
were treated with either vehicle or (5, 10 and 50 mM) curcumin for
24 hrs, after which cells were trypsanized, counted and equal
number of cells from each treatment group were cultured in
growth medium (containing 10% FBS) for an additional 4 days.
Our results show (Fig. 1B) that an exposure to low concentrations
of curcumin demonstrated proliferation that was similar to vehicle
control. However, when AtT20 cells were exposed to 50 mM
curcumin, they failed to proliferate in growth medium. These
results suggest that curcumin induced growth suppression is
irreversible.
We next questioned whether curcumin would have any effect on
the clonogenic property of AtT20 cells. AtT20 cells were seeded
(1000–3000 cells/well) in complete growth medium and allowed
to adhere for 24 hrs. The medium was then replaced with
complete growth medium containing the indicated concentrations
of curcumin, and ability of AtT20 cells to form colonies was
monitored over the next 14–21 days. Our results show (Fig. 1C)
that the ability of AtT20 cells to form colonies is decreased in
presence of curcumin. Significant inhibition (65.86%; p,0.05) of
colony formation was detected with 5 mM curcumin from 20 mM
curcumin concentrations, colony formation was completely
abolished (Fig. 1D).
Curcumin suppresses constitutively activated NFkB
activity, down regulates Bcl-xl and causes mitochondrial
membrane depolarization in AtT20 cells
We next questioned whether curcumin induced growth
suppression is due to suppression of NFkB activity. To address
this issue, AtT20 cells were transiently transfected with an NFkB-
Luciferase reporter gene [17]. AtT20 cells were treated with
vehicle or curcumin 5 and 50 mM for 4 hrs, and luciferase activity
was determined. Our results (Fig. 2A) show that in AtT20 cells
NFkB is constitutively active, and that curcumin inhibits this
activity in a concentration-dependent manner. We next ques-
tioned whether the curcumin -induced decreased NFkB transcrip-
tional activity would also result in decreased expression of NFkB
target genes, in particular those that regulate cell survival. To
address this issue, AtT20 cells were treated with either vehicle or
curcumin (5 and 50 mM) for 24 hrs, and equal amount of cell
lysates were examined for expression of pro-survival proteins. Our
results show (Fig. 2B) that curcumin caused a decrease in the
expression of pro-survival protein Bcl-xl. We next questioned
whether curcumin induced decreased Bcl-xl levels would shift the
balance of pro-apoptotic proteins and pro-survival proteins in
favor of pro-apoptotic proteins, thereby depolarizing the mito-
chondrial membrane. AtT20 cells were treated with either vehicle
or 5 and 50 mM curcumin for 24 hr, cells were washed and
incubated with JC-1 dye (a mitochondrial-specific dual fluores-
cence probe) according to the manufacturer’s instructions. In
intact cells JC-1 dye coalesces in the mitochondria to emit a red
fluorescence; however, in apoptotic cells with a depolarized
mitochondrial membrane, mitochondrial contents gain entry into
the cytosol, and hence JC-1 dye cannot accumulate in the
mitochondria and it enters the cytosol emitting a green
fluorescence. The dot plots show (Fig. 2C) that in a dose-
dependent manner curcumin treatment lead to increased green
fluorescence. Quantitation of the dot plots show (Fig. 3D) that in
vehicle treated cells 85.82% of the cells emitted a red fluorescence
while only 13.36% emitted green fluorescence. Likewise in 5 mM
curcumin treated AtT20 cells, 85.34% of the cells emitted a red
fluorescence while only 13.41% emitted a green fluorescence.
However, in 50 mM curcumin treated cells only 31.98% cells
emitted red fluorescence while 67.68% emitted green fluorescence.
These results demonstrate that in a concentration-dependent
manner curcumin treatment led to a significant reduction in the
number of cells with intact mitochondrial membranes.
Curcumin induced apoptosis in AtT20 cells
We next questioned whether the decreased expression of the
pro-survival protein, Bcl-xl, would lead to increased apoptosis. To
address this issue, AtT20 cells were treated with vehicle or
curcumin (5 and 50 mM) for 24 hrs, and equal amount of cell
lysates were subject to Western blotting with an anti-PARP Ab
that detects both, the total as well as cleaved form of PARP. Our
results show (Fig. 3A) that in a concentration-dependent manner,
curcumin caused increased cleavage of PARP. Next, we confirmed
whether curcumin induced apoptosis in AtT20 cells. To address
this issue, AtT20 cells were treated with vehicle or curcumin (5 and
50 mM) for 24 hrs, and propidium iodide and anexin V-FITC
staining was used to examine apoptosis. Our results show (Fig. 3B)
that curcumin induced a decrease in the live cell population with a
concomitant increase in the dead cell population.
Curcumin decreases secretion of ACTH
We next questioned whether curcumin would have any effect on
ACTH secretion in AtT20 cells. To address this issue, AtT20 cells
were treated with vehicle or curcumin (5 and 50 mM) for 24 hrs,
and the amount of ACTH secreted into the conditioned medium
(CM) was determined. Our data show (Fig. 4) that, in a
concentration-dependent manner curcumin decreased the secre-
tion of ACTH in AtT20 cells, with significant decrease (p,0.001)
being detected with concentrations as low as 35 mM. With 50 mM
curcumin, maximal suppression of ACTH secretion was achieved.
Note: To confirm that the observed decreases in ACTH were not
due to a direct effect of curcumin on the assay, 50 mM curcumin
was incubated with ACTH standard, and was found to have no
effect (data not shown).
Discussion
Approximately 15% of all intracranial tumors are of pituitary
origin. Although these tumors rarely metastasize, they do cause
significant pathological effects due to excess hormone secretion as
well as compression of the surrounding structures. Pituitary
corticotroph tumors secrete excess ACTH resulting in CD. The
progression of CD is accompanied by several pathological
conditions including diabetes, osteoporosis and hypertension [3].
Considering that CD was described almost 80 years ago, and to
date, the standard treatment for CD is surgery followed by
radiation, pharmacotherapy still remains a challenge. Recently,
our laboratory demonstrated for the first time that effective growth
suppression of prolactin and growth hormone producing tumor
cell could be achieved by using curcumin, a natural food additive
[1]. Subsequently, Schaaf et.al. confirmed our findings, and further
demonstrated the in vivo ability of curcumin to suppress pituitary
tumorigenesis [16]. However, the molecular mechanisms by which
curcumin suppresses pituitary tumorigenesis remain unknown. In
this study, we report that curcumin suppresses NFkB activity,
thereby modulating the expression of pro-survival genes, and
ultimately leading to mitochondrial apoptosis.
Our data show that curcumin in a concentration-dependent
manner inhibited the proliferation of pituitary corticotroph tumor
Corticotroph Tumor Suppression
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suppressive effects of curcumin are consistent with a recent report
confirming the growth inhibitory effects of curcumin on pituitary
tumor cells. Although in our study, we detected growth suppression
(by using the MTT assay) with 20 mMc u r c u m i n ,Schaaf et.al. report
significant growth suppression (by measuring 3[H] incorporation)
with concentrations as low as 5 mM [16]. This discrepancy between
the growth suppressive concentrations of curcumin could be
attributed to the sensitivities of the growth assays used in the two
studies. In general, the concentrations of curcumin used in both
studies were similar to those used in other in vitro studies
demonstrating the growth-suppressive effects of curcumin in different
tumor types [18–22]. Further, our study demonstrates that the ability
of curcumin to suppress corticotroph tumor cell proliferation was
irreversible. When AtT20 cells were exposed to curcumin for 24 hrs,
and subsequently placed in growth medium containing 10% FBS,
they failed to proliferate (Fig. 1B). In addition, the ability of AtT20
cells to form colonies (Fig. 1C) was blocked in a concentration-
dependent manner by curcumin, with significant inhibition detected
with concentrations as low as 5 mM curcumin, and a complete
blockade from concentrations of 20 mMo rh i g h e r( F i g .1 C & D ) .
We next wanted to identify the molecular mechanism by which
curcumin inhibits AtT20 cell proliferation. Previous work has shown
that curcumin exerts its anti-tumor property by suppressing TNFa
mediated NFkBactivation.CurcuminsuppressestheTNFa-induced
activation of IKK that leads to the inhibition of TNF-dependent
phosphorylation and degradation of IkBa and subsequent nuclear
translocation of the p65 subunitof NFkB to regulate gene expression
[11]. The target genes that are affected by this are several important
regulatorsofcellcycleprogression(cyclinDfamily),apoptosis(bcl-2),
regulators of cell migration and invasion (MMP 2 and MMP-9)
[11,23,24]. Further, constitutive activation of NFkBh a sb e e n
reported in cell lines as well as tumor samples and is believed to be
linked to tumor progression as well as drug resistance [25–28].
Figure 2. Curcumin suppresses constitutively activated NFkB activity, down regulates Bcl-xl and causes mitochondrial membrane
depolarization in AtT20 cells. (A) AtT20 cells were transiently transfected with an NFkB reporter gene, and after 24 hrs treated with either vehicle
or the indicated concentrations of curcumin for 4 hrs. Cells were washed and luciferase activity in cell lysates was determined. Normalized luciferase
activity was calculated, and data is presented as fold change over control. Each value is the mean 6SEM of 3 separate experiments each performed in
triplicates. * indicates significant difference from control, (p,0.05). (B) AtT20 cells were treated with either vehicle or indicated concentrations of
curcumin for 24 hrs. Cell lysates were harvested and equal amount of protein was subjected to western blotting with an anti-Bcl-xL Ab. The filter was
stripped and reprobed with anti- b tubulin Ab to confirm equal loading. Data shown is from a single experiment, and is a representative of 2
independent experiments yielding similar results. (C) AtT20 cells were treated with either vehicle or indicated concentrations of curcumin for 24 hrs.
Cells were washed and labeled with the dual fluorescence mitochondrial specific dye, JC-1, and analyzed by flowcytometry. The dot plots show that
in vehicle and 5 mM curcumin treated cells, the % of cells emitting green fluorescence is low, and is indicative of basal apoptosis. However, treatment
with 50 mM curcumin, that caused a decrease in Bcl-xL levels, significantly increased the intensity of green fluorescence. The dot plot shown is from a
single experiment that is representative of 3 independent experiments. When data from the light scatter plots were quantitated (D) as % of gated
cells, our data show that curcumin in a concentration-dependent manner, lead to increased membrane depolarization. Each value is the mean 6SEM
of 3 separate experiments. * indicates significant difference from control, (p,0.05).
doi:10.1371/journal.pone.0009893.g002
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effective method to regulate pituitary tumorigenesis. Our data show
(Fig. 2A) that, in a concentration-dependent manner, curcumin
suppresses constitutively activated NFkB in AtT20 cells. We next
questioned whether decreased NFkB transcriptional activity would
resultindecreasedexpressionoftargetgenesinvolvedincellsurvival.
To this end we examined the effect of curcumin on expression of the
bcl-2 family of pro-survival proteins. Our data show that in AtT20
cells we detect a robust expression of Bcl-xl, which is decreased in
response to curcumin treatment (Fig. 2B). Further, we observed that
curcumin treatment had no effect on the levels of bcl-2 (data not
shown). Our results are consistent with a recent reports demonstrat-
ing a central role for Bcl-xl in pituitary cell survival and apoptosis
[29,30]. Although it is known that changes in intracellular levels of
Bcl-xl can dramatically affect cell survival, its role in tumorigenesis
has been mostly examined in tumors of the hematopoetic system
[31,32]. Our data clearly demonstrate that Bcl-xl plays a major role
in regulating cell survival in pituitary corticotrophs, and manipulat-
ing its levels could provide a novel therapeutic avenue to suppress
corticotroph tumor growth.
Decreased Bcl-xl levels would lead to mitochondrial membrane
depolarization followed by cytochrome c release and execution of
the death pathway. We observed that consistent with the
decreased levels of Bcl-xl, curcumin treatment lead to mitochon-
drial membrane depolarization (Fig. 2C &D) and cleavage of
PARP and ultimately apoptosis (Fig. 3A &B).
Excess ACTH levels and hypercortisolemia are associated with
the progression of CD, and decreasing hormone levels is a
therapeutic goal. We next investigated whether curcumin would
have any effect on ACTH secretion in corticotrophs. Our data
show that, in a concentration-dependent manner, curcumin
decreased secretion of ACTH from AtT20 cells (Fig. 4). Our
results showing the decreased secretion of ACTH from AtT20 cells
are in agreement with similar observations reported by Schaaf et.al.
[16], and clearly demonstrate the potential of curcumin to achieve
the therapeutic goal of lowering hormone secretion.
In conclusion, we show that curcumin irreversibly inhibits
proliferation, induces apoptosis and abolishes clonogenic ability of
pituitary corticotroph tumor cells. The induction of apoptosis is
accompanied by decreased NFkB transcriptional activity and
expression of the pro-survival protein Bcl-xl. We also demonstrate
that curcumin suppresses ACTH secretion from pituitary
corticotroph tumor cells. Based on this we propose developing
curcumin as a novel therapeutic agent in the management of CD.
Materials and Methods
Chemicals and reagents
Curcumin was purchased from LTK laboratories (St. Paul,
MN). Anti -total PARP and -bclxl antibodies were purchased from
Figure 3. Curcumin induced apoptosis in AtT20 cells. (A) AtT20 cells were treated with the indicated concentration of curcumin for 24 hrs. Cell
lysates were harvested and equal amount of protein was subjected to western blotting with an anti-total PARP Ab, to detect apoptosis. Membrane
was stripped and reprobed with anti-b tubulin Ab to confirm equal loading. Data presented is from a single experiment, and is a representative of 3
separate experiments yielding similar results. (B) AtT20 cells were treated with the indicated concentration of curcumin for 24 hrs. Cell were washed
and labelled with anexinV-FITC and propidium iodide and analyzed by flow cytometry. Data are presented as % of gated cells. Each value is the mean
6SEM of 3 separate determinations from a single experiment, and is a representative of 3 separate experiments yielding similar results. * indicates
significant difference from control, (p,0.05).
doi:10.1371/journal.pone.0009893.g003
Figure 4. Curcumin decreases secretion of ACTH. AtT20 cells
were treated with the indicated concentrations of curcumin for 24 hrs,
and equal amount of CM were used to detect secreted ACTH. Data were
calculated as % of vehicle control and each value is the mean 6SEM of
4 separate experiments. * indicates significant difference from control,
(p,0.001).
doi:10.1371/journal.pone.0009893.g004
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idase (HRP)-conjugated secondary antibodies were purchased
from Upstate Biotechnology (Lake Placid, NY).
Cell culture
AtT20 cells were a kind gift by Dr. Pamela Mellon’s laboratory
(University of California San Diego, La Jolla, CA). Cells were
maintained in complete medium [DMEM (Mediatech, Manassas,
VA) containing 10% FBS (Gibco/Invitrogen, Grand Island, NY)
and 5 U/ml Penicillin/5 mg/ml Streptomycin]. Medium was
changed every 2–3 days, and sub-culturing was as required.
Assessment of cell proliferation
AtT20 cells in log phase were seeded (30,000 cells/well) on 96
well plates in complete medium (containing 10% FBS). After
24 hrs, cells were treated with curcumin in medium containing
0.5% FBS. Proliferation was assessed using the colorimetric MTT
assay as described previously [33].
Colony formation assays
Colony formation assays were performed as described [34].
Briefly, AtT20 cells growing in log phase were seeded (1000–
3000 cells/well in a 6 well plate) in growth medium (containing
10% FBS). After allowing the cells to adhere for 24 hrs, medium
was replaced with fresh growth medium containing the indicated
concentrations of curcumin. Cells were incubated at 37uC for 14–
21 days, with medium changes (including curcumin) every fourth
or fifth day. Crystal violet staining was used to visualize colonies.
Mitochondrial membrane depolarization assays
AtT20 cells were treated with the indicated amount of curcumin
for 24 hrs. According to the manufacturer’s protocol (Cell
Technologies Inc. Mountain View, CA) cells were washed, stained
with JC-1 dye, and then analyzed by flow cytometry.
Annexin V staining assays
Was performed as described before [1]. Briefly, AtT20 cells
were treated with the indicated amount of curcumin for 24 hrs.
This was followed by staining with annexin V - FITC and
propidium iodide, and analysis by flow cytometry.
Western blotting
After the indicated treatment, cell lysate preparation, protein
content determination and western blotting was performed as
described previously [1].
NFkB/Luciferase reporter gene assays
AtT20 cells were plated in 24 well plates, and 24 hrs later cells
were transfected with 0.8 mgo fN F kB/Luciferase plasmid [17]
(gift from Dr. S.C. Gautam, Detroit, MI); using Lipofectamine
2000 (Invitrogen) according to the manufacturers instruction.
After 18–24 hrs, medium was replaced with plating medium
containing the indicated concentration of curcumin. After 4 hrs
cells were lysed and luciferase activity was determined using a
commercial Luciferase assay kit (Promega, Madison, WI). Fold
change in NFkB-luc activity was calculated after normalization of
light units to mg of cell protein.
Measurement of ACTH
AtT20 cells were treated with the indicated concentrations of
curcumin for 24 hrs, and conditioned medium (CM) was
harvested, and ACTH concentration was determined by using a
commercial ACTH-RIA kit (MP Biomedicals, Solon, OH)
according to the manufacturer’s instructions.
Data analysis
Statistical significance was determined using Student’s t test or
one-way analysis of variance followed by Duncan’s multiple range
test as required.
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